G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
100 hedge funds and large institutions have $699M invested in G1 Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 26 reducing their positions, and 16 closing their positions.
118% more capital invested
Capital invested by funds: $320M → $699M (+$379M)
46% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 26
0% more funds holding
Funds holding: 100 → 100 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
14% less call options, than puts
Call options by funds: $231K | Put options by funds: $269K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$8.43M |
| 2 |
JP Morgan Chase
New York
|
+$5.79M |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$2.34M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.34M |
| 5 |
BlackRock
New York
|
+$1.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$6.17M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.12M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$3.1M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.87M |
| 5 |
Morgan Stanley
New York
|
-$1.81M |
GTHX Hedge Fund Activity: Q2 2020 in Review
100 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q2 2020, worth a combined $699M — up 118% from $320M a quarter earlier.
Fund positioning in GTHX was balanced in Q2 2020: 16 funds opened new positions, 16 closed out, 38 added to existing stakes and 26 trimmed.
The largest buyer was Candriam SCA, adding an estimated $8.43M. The largest seller was Deutsche Bank, cutting an estimated $6.17M.
- 100 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $699M of G1 Therapeutics, Inc. Common Stock stock for Q2 2020, up 118% quarter-over-quarter.
- 16 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q2 2020 and 16 closed out, a net change of 0 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q2 2020 was Candriam SCA, an estimated $8.43M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q2 2020 was Deutsche Bank, an estimated $6.17M sold.
Based on aggregated 13F filings for Q2 2020.